ST8154AA1
ST8154AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 2247025-59-6
- Formula: C36H51N5O8S
- Molecular Weight:713.88
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Drug-Linker Conjugates for ADC Isoforms
More
Biological Activity
Description
IC50 & Target
|
Traditional Cytotoxic Agents |
Chemical Information
-
CAS No. 2247025-59-6
-
Molecular Weight 713.88
-
Formula C36H51N5O8S
-
SMILES
OC([C@H]1CC[C@H](CNC(CCCCCN2C(CC(SCCCCC[C@H](NC([C@H]3CCC(N3)=O)=O)C(NC4=CC=CC=C4)=O)C2=O)=O)=O)CC1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)